Veterinary surgeon Noel Fitzpatrick, a pioneer of prosthetic implants, has launched what is being billed as Europe's most advanced neuro-orthopaedic centre for dogs and cats.
Fitzpatrick Referrals' £10m facilities at Eashing, near Godalming, Surrey, have been set up to offer a world-class "centre of excellence" in diagnosis, surgery and rehabilitation.
Facilities at the centre include:
Noel was the first veterinary surgeon to successfully apply a prosthetic limb to a dog where both bone and skin can grow into metal - a technique with far-reaching cross-over potential for human surgery. He believes in "pushing the boundaries" and creating solutions for conditions that may never have previously been treatable, and says the work being done at Eashing also provides valuable experience for medical science as a whole. Examples include cartilage resurfacing, limb-sparing cancer surgery and spinal vertebral fusion.
Professor Gordon Blunn of the Centre for Biomedical Engineering, Institute of Orthopaedics and Musculo-Skeletal Science at University College London said: "Orthopaedic conditions and diseases are common to both human beings and to animals. For example osteoarthritis is debilitating condition seen in humans, cats and dogs. Bone cancer which can lead to loss of life in humans and is usually associated with the peripheral skeleton is also seen in the peripheral skeleton of large dog breeds. Translation of ideas, orthopaedic practice and treatments, from humans to the veterinary field and visa versa has considerable advantages to all animals including dogs, cats and man. Noel Fitzpatrick is pioneering this concept and his work in limb reconstruction for dogs and cats has already had benefits in both veterinary and human orthopaedic practice."
DJ Chris Evans is one satisfied client. His dog, Enzo, a German Shepherd, was "written off" by other vets after becoming paralysed with two herniated discs. Noel fitted Enzo with two bolts to replace the collapsed disc and keep the vertebrae apart. The surgery was followed by extensive physiotherapy and hydrotherapy to enable Enzo to learn to walk again.
Chris said: "Noel lives out his dreams with boundless curiosity, ambition and genius, the product of which is hundreds, soon to be thousands, of fixed pets and happy owners - like me. I have huge respect for his endeavour, his integrity and his compassion and to me he's a superhero-vetman who will leave no stone unturned in his quest to heal, to create and to comfort. He thinks of solutions to medical problems that I'm sure no-one else could even dream of, let alone think of. Actually - I don't think he ever sleeps!"
The invaluable work done by equestrian vets in the UK is to be recognised with a new award sponsored by leading equine insurance provider Petplan Equine at the Animal Health Trust Awards in November. The ‘Petplan Equine Vet of the Year' award people's vote will reflect the huge contribution made by vets to the equine community.
Owners and riders will be able to nominate their equine vet for the award if they feel that they are deserving of the recognition that this accolade would bring. Veterinary practice personnel are also encouraged to nominate a colleague who they feel has gone beyond the call of duty. Leaflets have been sent to practices across the UK outlining how to nominate and people can also register through the Petplan Equine website www.petplanequine.co.uk. A short list will be drawn up from the nominations received and an independent panel will decide the winner, who will receive his or her award at the Animal Health Trust Equestrian Awards in London on November 6th 2008.
This year marks the 20th anniversary of the Animal Health Trust Equestrian Awards, which recognise the outstanding achievements made by horses, riders, owners and trainers throughout the equestrian world. This milestone coincides with Petplan Equine's 20th anniversary and, since 1994 when the Petplan Equine Charitable Trust was founded, it has raised over £5 million, almost £500,000 of which has been donated to the AHT to fund research and development.
Jo Whitaker of Petplan Equine says: "It has been a privilege to be involved with the AHT Awards over the years and we look forward to this exciting 20th anniversary year. Petplan Equine has sponsored the Eventing Award for the past three years but this new award will recognise the commitment and hard work of people within the equine veterinary profession and the service they provide to horse owners. Horse welfare is paramount at Petplan Equine and we are committed to promoting responsible horse ownership, through our wide range of policies, our charitable contributions and our Horse Handbook. This award will give the equine community the opportunity to acknowledge and celebrate the vet who has made the most outstanding contribution to the care of horses."
To nominate go to www.petplanequine.co.uk. The closing date for nomination is 3rd October 2008.
Epiphen, Vétoquinol's canine anti-epileptic drug, has been re-launched with new packaging and a useful dosing syringe.
"Some of our customers reported that they were having difficulty administering the drops accurately," explains Slavica Sobot, Product Manager. "So with this in mind, we have introduced a new plug-on syringe which will make it even easier for pet owners to dose accurately. The syringe will prevent the risk of inaccurate dosing through ‘flooding' from the dropper."
For more information, please call the Vétoquinol help line on 0800 169 8197 or contact your Vétoquinol representative.
In the most recent Petplan Pet Census, an annual study of pet ownership in the UK, 97% of vets reported that a lack of funds had led to owners choosing euthanasia over treatment.
Whilst some cases are the result of one-off ‘emergency' treatment, manageable long-term conditions are often at the root of much unnecessary euthanasia because owners simply cannot afford the cost of ongoing treatment. Reported increases in pet obesity and diabetes, arthritis and behavioural problems have all been cited in the Pet Census as common causes of increased and ongoing vet bills.
Vets have been reporting a rise in diseases that are related to obesity in companion animals for some time and with the Petplan Pet Census panel of almost two hundred (198) UK veterinary practices reporting that more than one third (36%) of all dogs and one quarter (29%) of cats they treat are obese, the future for many pets looks bleak. More than half (53%) of vets say that cases of cat and dog diabetes are on the increase. Obesity is actually bucking the trend of more historically significant diseases, including kennel cough and feline leukaemia, which are either remaining static or decreasing.
The number of pets with behavioural problems is also on the rise, with more than half of vets (55%) reporting an increase and most (95%) practices offering support for these animals. Effective treatment is not a quick-fix solution and requires changes to the owner's lifestyle and lengthy work with experts in the field.
Petplan Vet of the Year, Brian Faulkner said: "I think it is a common misconception that the predicament forcing pet owners to euthanase their pet is the out-of-the-blue, one-off vet fees for emergencies. But in fact we are noticing that owners whose pets have on-going illnesses such as diabetes and even behavioural problems that are very manageable are being faced with the dreadful decision to have to euthanase than face the ongoing financial burden. It's even more devastating when the owners have actually taken out an insurance policy but the nature of the policy only covers treatment of any one condition for up to one year. I always advise people to make sure their policies do not cap the time period over which any one condition is covered to avoid this very problem as more comprehensive insurers are then unable to offer cover on a pre-existing condition."
Simon Wheeler, Head of Marketing at Petplan, said: "We receive over 8,700 claims per week and of the top ten claims, six could be recurrent manageable conditions, such as diabetes or arthritis - the very animals that are currently most at risk of being euthanased."
Research announced simultaneously by Sainsbury's Finance has reached similar conclusions. Sainsbury's found that:
Sainsbury's believes that there are two main reasons for this tragic problem: advances in veterinary care leading to increased costs, and the large number (55%) of pets that remain uninsured.
Ed's note: Isn't it time that pet insurance became compulsory?
Emily Holbrook MRCVS, Garth Tozer MRCVS, Dr Richard Dixon and Ken Davison MRCVS have all won a Best Practice Employer Award from Novartis Animal Health after glowing nominations from the staff at their practices.
In addition, Katherine Corbett VN from Nine Lives Veterinary Centre won a special new award, worth £500, for the veterinary nurse that in the judges' opinion had best used the opportunities given to her by her boss, Emily Holbrook.
Katherine's first question when told of her win really demonstrates the commitment that veterinary nurses will give a good boss: "Can I spend it on buying one of Kruuse's Buster ICU cages for the practice? Emily has given me so much; I'd love to give something back."
Rachel Smithson, Marketing Manager at Novartis said: "All of our winners were asked what steps they take to ensure a happy team. Their answers were almost unanimous. Empower your staff. Give them responsibility, and if that means accepting the occasional mistake, then do so. Praise them for a job well done. Thank them regularly. Not only will it make your practice a better working environment, but as Katherine demonstrates, your staff will probably go to extraordinary lengths to support you. That translates into a more profitable practice, and higher standards of veterinary care."
The story is covered in full in the August and September editions of Veterinary Practice magazine, downloadable from www.vetsurgeon.org
Sarah Palmer (left) of Novartis Animal Health makes the presentation to head nurse Katherine Corbett and veterinary surgeon Emily Holbrook of Nine Lives Veterinary Practice; behind them are Anne Corbett (receptionist), Lindsay Harrison (nursing assistant), and Laura Steele (veterinary surgeon).
Kenneth Agnew from Novartis Animal Health prepares to present Kenneth Davison with his Best Practice Employer Award, whilst the team toast their boss.
Veterinary Nursing Assistant Abby Brown (left) and Abby Roberts from Novartis Animal Health toast Garth Tozer, Novartis Best Practice Employer Award winner.
Donna Lewis (BVNA), and Novartis Animal Health CEO George Gunn present Dr Richard Dixon with his award.
Boehringer Ingelheim has announced the results of an independent three-year study which demonstrates that dogs suffering from the most common type of heart failure lived longer (average time in the study of 267 days vs. 140 days) when treated with the product Vetmedin (pimobendan) compared with the ACE inhibitor benazepril hydrochloride.
According to Boehringer, results from the QUEST (Quality of Life and Extension of Survival Time) study, published in the September/October 2008 issue of the Journal of Veterinary Internal Medicine, mark a significant milestone in canine cardiac health.
25% of all small to medium-sized dogs over the age of seven are likely to suffer from heart disease at some point in their life, and 75% of those cases are caused by myxomatous mitral valve disease (MMVD), sometimes known as "valvular insufficiency" or "endocardiosis".
Adrian Boswood from the Royal Veterinary College, London, a Veterinary Cardiology Specialist and a lead-investigator on the study, said: "With QUEST demonstrating that dogs treated with Vetmedin live on average nearly twice as long as those on benazepril, it is now time for us as veterinary cardiologists and practising veterinarians to look again at how we are treating our patients suffering from this serious condition."
Dr. Michael O'Grady from the Ontario Veterinary College, University of Guelph, a fellow lead-investigator added, "The QUEST study provides compelling evidence that dogs with the most common form of heart failure should be receiving Vetmedin® as an essential part of their treatment regimen."
QUEST is the largest international study ever conducted looking at treatment for congestive heart failure (CHF) caused by MMVD, with 260 dogs studied in 11 countries, across three continents, over a period of three years.
The study was conducted by a team of 32 independent veterinary cardiologists from Australia, Canada, France, Germany and the United Kingdom among other countries.
For more information on the QUEST study and on CHF caused by MMVD, see http://www.questtrial.com/
Merial has launched a new website where you can test your NSAID knowledge and get the chance to win a £50 book voucher. There’s a new winner every month.
The website, http://www.osteoarthritisindogs.co.uk is designed to help practice staff understand more about canine osteoarthritis (OA) and effective management of the condition. The site covers every aspect of canine OA, including treatments and non-pharmacological management strategies. There is also a section for dog owners where practice staff can direct their customers for further information.
Merial product manager Claire Parry-Baggott said: “The practice section is password protected but registration is quite straightforward. The test itself consists of 10 multi-choice questions and your test results are returned within a matter of a few seconds.”
Claire added: "Canine osteoarthritis is a challenging area on its own but is further complicated by the choice of NSAIDs that serve the market. All NSAIDs inhibit the COX-2 enzyme which plays the key role in the development of pain and inflammation. However, traditional NSAIDs also inhibit COX-1 to widely varying degrees. This is a beneficial enzyme that plays an important role in normal physiological functioning. The resulting unwanted side-effects of COX-1 inhibition may hinder therapy, however this is not yet recognised by many vet practices.
“This site will help vets and practice staff better understand canine OA, whilst giving a clearer picture of how different NSAID’s interact with COX-1 and COX-2. The new generation NSAID – firocoxib (Previcox®), selects COX-2 whilst sparing COX-1 and so is a real step forward in the treatment of canine OA.”
The first coxib for the treatment of osteoarthritis (OA) in dogs, PREVICOX® (Merial), has now been licensed for the relief of post-operative pain and inflammation following soft tissue surgery.
"PREVICOX is the first coxib specifically designed for dogs, and now vets have another reason to use it," said product manager Claire Parry-Baggott. "In addition to the osteoarthritis claim, it is now also proven for use following soft tissue surgery with no adverse effect on bleeding times, haematology or biochemistry.
She added: "With its rapid onset of action and once daily dosing vets can prescribe PREVICOX with confidence at a dose rate of 5mg/kg, two hours pre-surgery and for up to three days including the day of surgery".
To help practice staff explain the importance of the owner's role in after surgery care, and the benefits of using PREVICOX, Merial has produced a practice guide for dog owners following soft tissue surgery. The guide deals with all areas of surgery aftercare including dietary advice, post surgery exercise and wound care. For copies, please contact your local Merial Territory Manager, or call 0870 6000 123.
Defra has announced the detection of Bluetongue in 18 imported cattle on premises near Bishop Auckland, County Durham. The animals originated from within the BTV8 Restricted Zone in Germany and were detected as a result of post-import testing carried out by Defra on all Bluetongue susceptible animals arriving from Continental Europe.
This is the fourth incidence of infected animals being imported to the UK. Alongside the premises in East Sussex, Hertfordshire and Devon identified in August, the imported animals will remain under restrictions.
As of 1 September the whole of England and Wales is now in a Protection Zone and approximately 30 million doses of vaccine have so far been made available to farmers throughout England and Wales to protect their stock. However, it may take up to six to eight weeks from now for livestock keepers in the North of England and Wales to have had sufficient opportunity to vaccinate their livestock and to gain immunity (at least three weeks in sheep, and six weeks in cattle).
To allow livestock keepers in those areas sufficient opportunity to protect their animals, and while further veterinary investigations are carried out, these particular infected animals will remain under restriction until late October. Any further positive import cases detected may also be restricted for a period of time depending on veterinary risk assessment, while vaccination continues.
Deputy Chief Veterinary Officer, Alick Simmons said: "This incident shows how important it is for farmers to consider potential disease risks when buying stock, regardless of source. Buyers need to consider how best to protect their own businesses and those of their neighbours and make sure they are clear about the stock they are intending to buy.
"I also want to remind farmers about the importance of vaccination. It is the only effective tool to protect susceptible animals from Bluetongue. Recent evidence indicates a drop or delay in vaccine take-up in counties recently brought into the Protection Zone. Sales data for some of those counties suggest that the number of animals vaccinated in these areas could be as low as one in three, and in Northumberland and Cumbria, the most recent counties brought into the Protection Zone, as low as one in five.
"The threat from Bluetongue is present and real, as shown by the most recent import cases. Vaccination as a preventive measure is therefore more important than ever, so the message to the industry remains clear: don't hesitate, vaccinate".
Pfizer Animal Health has confirmed that the agreement to acquire multiple product franchises from the Schering-Plough Corporation has been completed - and approved by the European Commission. Pfizer has acquired these assets for approximately euro 116 million in cash.
The agreement covers all European Union countries and the franchises include all major animal health species including cattle, swine, equine and companion animal. Pfizer executives say the agreement leaves them with the most in-depth coverage of therapeutic areas, and the most highly recognised brands, in the industry. Precise details of the agreement are not being released although additional information on the products concerned will be the subject of further announcements in due course.
Pfizer has acquired certain rights to the following products in the European Economic Area:
Albert Bourla, President of Pfizer Animal Health in Europe, said: "This represents a significant expansion of our product portfolio and strengthens our long term commitment not just to veterinary surgeons, but also to farmers and pet owners. Pfizer spends hundreds of millions of dollars on research and development every year, and brings more new products to market than any other company, but when the opportunity arose to add well known, well respected brands to a portfolio that is already extremely strong, we had little hesitation in taking it."
Researchers at the Royal Veterinary College (RVC) have developed a system that eliminates the need for antibiotics and resistance genes in the engineering of industrial and medical products.
The method involves safer, less costly alternatives and is well suited for industrial production of many biofuels and biopharmaceuticals. This research has been published in the online access journal BMC Biotechnology.
Genetic engineering underpins much of biotechnology, and antibiotic selection of engineered strains is a key tool. Unfortunately, antibiotic selection methods risk spreading resistance traits, particularly as biotechnology products move into the environment and clinic. There have been alternatives, but none are satisfactory for wide application.
Gene targeting is the insertion of DNA into specific sites or genes within the genome of selected cells in order to alter gene expression for a particular purpose.
While working on gene targeting in bacteria, RVC researchers discovered that a well-known interaction between a cell membrane synthesis gene and the biocide triclosan could be exploited for strain selection. Surprisingly, triclosan selection performs better than conventional antibiotic selection.
"We think this simple technology is well suited for industrial scale fermentations that produce a range of valuable products, including bio-fuels and bio-pharmaceuticals," said Dr Liam Good, at the Royal Veterinary College and lead researcher on the project. "More importantly, the new system is relatively safe and inexpensive, because the gene is native in all bacteria and triclosan is approved for use in many household applications."
The research was carried out with Dr Shan Goh of the Department of Cell and Molecular Biology, Karolinska Institute, Stockholm.
The University of Nottingham, with funding worth £2.2m, is to carry out a study of the most common cause of Bovine Mastitis in the UK - Streptococcus uberis (S. uberis). If researchers can identify which parts of the bacteria enable the infection their results could lead to the production of an effective vaccine.
James Leigh, Professor of Molecular Bacteriology, who has recently joined the School of Veterinary Medicine and Science, said: "We hope to uncover bacterial antigens of potential use in vaccines aimed at preventing bovine mastitis and provide a detailed understanding of how animals can fight off the disease."
S. uberis is responsible for a significant proportion of clinical mastitis worldwide - but unlike many other bacteria that cause the disease, S. uberis is also in the environment - it is found in pasture and bedding and can even colonise the cow at other body sites with no ill effect - so it is difficult to see how it can be controlled by changes to animal husbandry and milking-time hygiene.
With funding from the Biotechnology and Biological Sciences Research Council (BBSRC) the School of Veterinary Medicine and Science has established research laboratories at the Institute for Animal Health (IAH). The project is being conducted in collaboration with Dr Tracey Coffey's Bovine Genomics group based at IAH and other groups at the Royal Veterinary College, the US Department of Agriculture in the UK and the University of Oxford.
Professor Leigh said: "We will use state-of-the-art molecular technology to determine the differences between strains of S. uberis that can and cannot cause disease. Proteins that are only present in the disease causing strains hold the key to determining which components are essential for infection. We will show which of these proteins are most likely to make an effective vaccine by producing strains of S. uberis which lack the ability to produce each of these proteins; if a strain lacking a particular protein is less able to cause disease then this protein is important for the disease process and becomes a candidate for vaccine development."
The team also want to identify any parts of the immune response in the dairy cow which can be altered to prevent the disease - this information could subsequently be used to develop drugs that interfere with the chemical messages that lead to inflammation and therefore reduce the level of disease.
The British Equine Veterinary Association (BEVA) welfare award 2008, sponsored by The Blue Cross, has been presented to the Retraining of Racehorses (RoR) organisation for their contributions to equine welfare in support of the re-training and re-homing of racehorses.
The award, which was introduced by BEVA in conjunction with The Blue Cross animal welfare charity eight years ago, is a formal recognition of significant contributions made by veterinary surgeons and others to equine welfare.
It was presented to Ron Huggins, trustee of the ROR and an owner and breeder of racehorses, at the 47th BEVA Annual Congress in Liverpool on Friday 12 September 2008, by Kerstin Alford, equine welfare director of The Blue Cross.
Kerstin said: "The financial support that RoR provides for charitable racehorse rehabilitation centres, together with their education programme to help owners and riders of former racehorses, make them very worthy recipients of this award."
Di Arbuthnot, director of operations said: "RoR are delighted to receive this prestigious award to recognise the work the charity does for former racehorses to provide them with a life after racing."
Retraining of Racehorses was established in 2000 by the British Horseracing Authority. Its aim is to raise funds from the British racing industry to provide and maintain facilities for the care, retraining and rehoming of former racehorses. Under the direction of the chairman of the trustees Peter Deal, the RoR has become recognised as a vital component of the racing industry.
The Blue Cross was founded in 1897 to care for working horses on the streets of London, and equine welfare still plays a vital role in its work today. The charity rehabilitates and rehomes over a hundred horses and ponies every year at its equine centres in Burford (Oxon) and Rolleston-on-Dove (Staffordshire). A third facility in Northiam (East Sussex) provides rest and retirement for Blue Cross equines.
Fort Dodge, which supplies Bluetongue vaccine in continental Europe, has licensed its cattle vaccine in the UK and is now launching the product onto the UK market.
The company has already won and met tenders from several European governments, including France, Spain, Italy, Portugal Germany, Switzerland, Belgium and the Czech Republic for its Zulvac 8® Bovis vaccine and says it is the only international company to have produced vaccines for the most commonly occurring serotypes of the disease including 8, 4 and 1.
Approved by the VMD with a Provisional Marketing Authorisation, Zulvac 8 is available in 50 dose and 10 dose packs. The key claims are active immunisation against Bluetongue serotype 8 of cattle from 2.5 months old and a significant reduction of viraemia.
The vaccine is administered in 2 x 2 ml doses at three week intervals given by intra muscular injection and the product is supported by a fixed 2ml multidose applicator with Sterimatic needle protector and cleaning system to ensure accurate dosing and hygienic conditions.
John Hanley, Managing Director of Fort Dodge UK, said: "We were first to market with our Zulvac 8 product in three European countries and have received an Award for Agricultural Merit from the Spanish Government for our work in Bluetongue control. Following the licensing of Zulvac 8 Bovis in the UK we now have the opportunity to launch the product onto the UK market.
"In terms of pricing, Zulvac 8 is competitive per dose against other products in the market and it is supported by the experience gained in Europe with millions of animals already vaccinated. We're delighted that the VMD have authorised the vaccine and believe its availability can play a key role in protecting the UK's cattle from this dreadful disease."
The product is authorised for use by cattle farmers in the protection zone only, and will require veterinary prescription. Farmers can administer the vaccine to their cattle and the 2ml intra-muscular injection will be an advantage in aiding administration especially when used with Zulvac Bovis applicator with sterimatic needle protector and cleaning system.
The first batches will be available from veterinary wholesalers from week commencing 22nd September 2008.
Vets Now, the UK's dedicated Out Of Hours emergency vets with 32 clinics across the UK is launching a new recruitment initiative whereby vets with two years post qualified small animal experience have the opportunity to experience life working at the cutting edge of Emergency and Critical Care (ECC) through a range of new flexible short term contracts.
ECC represents a new, exciting and growing sector in the UK and Vets Now is offering vets a range of short to medium term flexible contracts which will enable you to develop new clinical skills in an exciting, fast paced environment. The contracts will appeal to any vet who is looking to gain experience working in ECC either with a view to pursuing a career in this specialised area or returning to daytime practice equipped with new clinical skills.
Speaking about the new contracts being offered, Fiona Dewar, HR Director for Vets Now SAid: "The nature of ECC medicine means that there is never a dull moment in our clinics and we tend to attract young, dynamic professionals who are keen to develop new clinical skills and have a more flexible working package. We know from experience that long term contracts don't appeal to everyone and we want to attract the best vets to come and work for us, whether it's for a three month contract or a twelve month contract with the added option of becoming permanent."
For more information about the range of contracts in one of Vets Now's 32 clinics, please contact Pauline Aitken, Vets Now Recruitment Manager on 0800 033 6466.
CEVA Animal Health, manufacturer of pheromonatherapy products, D.A.P.® and Feliway®, has launched a new website - http://www.petfireworkfear.co.uk/ - and a new leaflet and waiting room poster to support its ‘Remember, remember your pets this November' campaign which is backed by the PDSA, FAB (Feline Advisory Bureau), the APBC (Association of Pet Behaviour Counsellors) and Sound Therapy 4 Pets.
The website features a comprehensive range of information including hints and tips on preparing pets for the firework festivities, how to spot signs of stress in cats and dogs, what to do if pets go missing or are injured, fireworks and the law and information on pheromonatherapy.
"The new site is a one stop shop for information on how to look after pets during the firework season and the precautions that owners should take to help pets cope with their fear of loud noises," says Lucy Brett, product manager at CEVA Animal Health. "Veterinary practices can help highlight these precautions by linking their websites to the ‘Remember, remember your pets this November' site."
A downloadable PR toolkit is also available from the website to enable veterinary practices to highlight the campaign to local pet owners. To request a copy of the ‘Remember, remember your pets this November' information pack, which includes details on CEVA's ‘Promote Your Practice' competition, please call Lucy Brett at CEVA on 01494 781510.
Intervet / Schering Plough Animal Health has launched Leventa, an easily administered once daily, liquid treatment for canine hypothyroidism.
Leventa is a low volume liquid formulation of levothyroxine sodium which provides the thyroxine needed by dogs with hypothyroidism. The company says it is readily accepted.
Until now, thyroxine has only been available in a tablet format. Leventa comes in a single presentation 30 ml bottle with a dosing syringe suitable for all weights of dogs, allowing straightforward storage and stock control.
Leventa enables accurate dosing and easy dose titration. The ready-to-dispense pack avoids time-consuming tablet dispensing and handling of medications.
In addition to the practical compliance benefits of the liquid format, Intervet / Schering Plough says Leventa also offers excellent bio-availability1. In trials, 79% of dogs stabilised on the once daily starting dose of 20g/kg avoiding lengthy stabilisation2.
Vicki Winslet, Veterinary Advisor at Intervet / Schering Plough said: "One of the greatest challenges faced by vets for effective treatment is owner compliance. Leventa overcomes this issue with a simple syringe dose replacing the need for tablets of varying sizes and quantities."
One of the most common endocrine disorders in dogs but difficult to diagnose, hypothyroidism can lead to a variety of issues including weight gain, lethargy and coat problems (including dullness, loss or thinning). It can also cause insulin resistance in diabetic dogs.
The launch of Leventa further extends Intervet / Schering Plough's endocrine portfolio which includes Caninsulin, developed for the treatment of diabetes in small animals and Vidalta, a once daily treatment for hyperthyroidism in cats which is already proving extremely popular with the profession.
For further information, please contact your Intervet/Schering-Plough account manager or telephone the company's Veterinary Support Group on 01908 685685.
1. Le Traon G, Burgaud S, Horspool LJ. (2008) Pharmacokinetics of total thyroxine in dogs after administration of an oral solution of levothyroxine sodium. J Vet Pharmacol Ther 31:95-101.2. Gommeren K, Benchekroun G, Brennan S.F, Burgaud S, Daminet S, Horspool L.J.I, Le Traon G, Rosenberg D, Mooney C.T (2008) A novel L-thyroxine solution is a safe and effective once daily treatment for canine hypothyroidism. In:Proceedings BSAVA congress 2008 , 3-6 April Birmingham, UK pp487-488
Vets Now Limited, the out-of-hours emergency care provider, has been announced as a finalist in the Scottish region of the Bank of Scotland Corporate £35 Million Entrepreneur Challenge. The company will now compete with four other businesses to secure a funding package of up to £5 million, free of interest and charges for three years.
Managing Director, Richard Dixon, must now present his business case to a judging panel featuring two well known and incredibly successful entrepreneurs. Willie Haughey from City Refrigeration and John Anderson from The Entrepreneurial Exchange will be joined on the panel by senior representatives from Bank of Scotland Corporate and Deloitte. The panel will be grilling all five finalists on their future business plans, as well as looking for someone with an entrepreneurial flair, spirit and vision that sets them apart from the rest and makes them an outstanding choice to receive the once in a lifetime funding package that could change the face of the business.
The judging process will take place on Thursday 2 October and will be followed that evening by a dinner and award ceremony at Stirling Castle, where the winner will be announced.
For more information visit http://www.theboschallenge.co.uk/
Bayer Animal Health has launched Renalzin®, a feed additive for the management of Chronic Renal Disease (CRD), the leading cause of morbidity and mortality, especially in older cats1.
One-third of all cats over 15 years of age have CRD2, but the disease often remains undetected until the cat suddenly falls ill, by which stage 85% of kidney function may have already been lost3. The clinical signs are often subtle and non-specific, and diagnosis is complicated by the fact that changes in laboratory values occur relatively late in the disease.
Dr. Dennis Chew, specialist in veterinary urology and nephrology at the Ohio State University, said: "Most veterinary surgeons understand that CRD affects many cats, especially as they age, and is a leading cause of death. CRD is difficult to identify in early stages - early intervention with treatment can prevent progression of CRD to those with more serious kidney deficits. Restriction of dietary phosphorus intake is known to be a pivotal beneficial step in the stabilisation of CRD. Renalzin is a paste specifically formulated for cats that prevents dietary phosphate absorption across the intestine - a beneficial effect is gained when added to the cat's normal diet or to a veterinary renal diet".
The main ingredient of Renalzin is Bayer-registered Lantharenol® (lanthanum carbonate), a phosphate binder which binds to dietary phosphate within the gastrointestinal tract. According to the company, this renders it indigestible and thereby eases the burden on the already damaged kidneys.
Renalzin contains two additional ingredients - kaolin and vitamin E. Kaolin is a toxin binder which helps to reduce the absorption of toxins from the gastrointestinal tract. Vitamin E is known to reduce free radicals, improving immunity and protecting the integrity of cell membranes.
Bayer says that clinical studies demonstrate that Renalzin significantly increases faecal elimination and decreases urinary excretion of phosphorus 5. The product also decreases phosphate digestibility (absorption) in cats that are on both high and lower phosphate diets6. In addition, studies have shown that Renalzin causes a decrease in serum phosphate levels in cats with standard maintenance diets non-restricted in phosphorus7. Finally, a clinical trial in feline CRD patients revealed that taking Renalzin resulted in improvements in general clinical examination parameters as assessed by their veterinary surgeons over a two month period in cats on a normal diet7.
Renalzin comes in a pump applicator. One pump action provides 1 ml, with 2 ml being the recommended daily dose applied to and/or mixed with the cat's food. Having a neutral taste and being odourless, Renalzin® does not change the flavour of the cat's food and is flexible for clients to use as it can be given once or twice daily depending on the cat's feeding pattern.
References1 Lulich JP, O'Brien TD, Osbourne CA, Polzin DJ. Feline renal failure: questions, answers, questions. Cd Cont Ed Pract Vet 1992, 14(2): 127 - 151.2 Polzin DJ, Osbourne CA, Adams LG, Lulich JP. Medical management of feline chronic renal failure. In, Bonagura JD, Kirk RW (eds). Current Veterinarian Therapy X1. Philadelphia, PA, Saunders, 1992: 848-853.3 Grauer GF. Early detection of renal damage and disease in dogs and cats. Vet Clin Small Animal 2005, 35: 581-596.4 http://en.wikipedia.org/wiki/Lanthanum_carbonate.5 Schmidt B et al Bay 78-1887, J Vet Pharmacol Therap 2006, 29 (Suppl 1): 206-2076 Schmidt B, Spiecker-Hauser U, Gropp J. Effecrt of Lantharenol® on apparent phosphorus absorption from a conventional feline maintenance diet and a renal diet for cats. Proc Soc Nutr Physiol (2008) 17, in press.7 Data submitted for publication.
It's National Veterinary Nurse Week from 26th October to 1st November and vet nurses across the country will be raising awareness of the important job they do in caring for the nation's pets. Bonny Millar CVT(USA), RVN, REVN, Vice President of the BVNA and VN week organiser has called for vets and practice managers to support the initiative.
She said: "This is an ideal opportunity for practices to use their nurses to full effect. A lot of our efforts go on behind the scenes and so nurses are sometimes not fully appreciated by pet owners. We are encouraging practices to get their nurses out at front of house, running clinics and offering clients help and expert advice. Reducing barriers and educating the wider public about the role of the vet nurse can only be a good thing. Vets and practice managers know what a great contribution a good vet nurse can make to the practice and we would love to see them make a big effort to be ‘loud and proud' during National VN Week."
Bonnie added: "Last year hundreds of veterinary nurses took part in VN Week and we raised over £5000 for charity. This year our nominated charity is the Animal Cancer Trust so I hope practices really support their nurses in helping raise money for this important cause."
The British Veterinary Nursing Association is co-ordinating the various activities going on around the country and has arranged two pet health check days in Roundhay Park in Leeds on 26th October and Kensington Gardens in London on 1st November, sponsored by Hill's Pet Nutrition. Nurses are also being encouraged to make a special effort with prizes on offer thanks to sponsors Animalcare (Satellite Navigation system), Merial (lap top) and Vetoquinol (Nintendo Wii) for the most innovative event, most public involvement and most money raised for charity.
Further information and a registration pack is available from the BVNA http://www.bvna.org.uk/ (Tel 01279 408644). Any members of the practice interested in keeping up to date with the activities planned for VN Week can also visit the blog for the event at http://vnweek.wordpress.com/
A new guide - written by a vet and for vets - looking at the causes and treatment of pituitary tumours in rats has been produced in conjunction with the UK's first dedicated pet rat rescue charity, CavyRescue.
Written by exotics certificate holder Mark Rowland BVSc CertZooMed MRCVS, the guide discusses the illness as well as suggests treatments, many of which are not routinely used in the treatment of this condition.
Stella Hulott from the charity said: "Over the last ten years' one of the most common questions we, as a high profile pet rat rescue, get asked about is pituitary tumours in rats. The symptoms can be disturbing and not often attributed to the real cause.
"To date there has been very little information available about pituitary tumours in rats, so we felt the need to share our vet's knowledge in order to help reduce the amount of unnecessary suffering caused by this sadly very common illness."
The guide will be emailed out to those veterinary practices that have email access. Alternatively, you can download it here: http://www.cavyrescue.co.uk/pituitary-tumours-in-rats.pdf
The British Veterinary Association has welcomed the British Veterinary Nursing Association and the Veterinary Practice Management Association as Affiliate members.
Affiliate and Associate are newly activated BVA membership categories, and the election of BVNA and the VPMA as Affiliates also encourages any of their suitably qualified members to apply for Associate membership of the BVA.
According to the BVA, Affiliate status in no way affects an organisation's own remit and responsibilities towards its members. What it does mean is that Affiliates can benefit from the BVA's knowledge and expertise in such areas as lobbying and marketing.
In welcoming BVNA and VPMA newly elected BVA President Nicky Paull said: "I am delighted that my Presidential year coincides with the BVA family embracing both veterinary nurses and veterinary practice managers. Both are integral members of the veterinary team and we believe that our new relationship will bring lasting benefits to all parties. BVA looks forward to supporting our new Affiliates in promoting the professionalism of both veterinary nursing and veterinary practice management not only within the profession but to the wider community.
These are exciting, if challenging times, for the veterinary community world-wide and I have no doubt that our new relationship will strengthen not only our individual associations but the profession as a whole."
Cystease® S, CEVA Animal Health's urinary tract support product for cats, is now available in a new 100 tablet pack size for greater convenience to the practice.
CEVA`s small animal veterinary advisor Fraser Broadfoot said: "Previously Cystease® S was only available in 300 tablet packs. The new 100 tablet pack size makes the product easier to store in the practice and easier to dispense to clients."
To help vets gain easy access to information on Feline Lower Urinary Tract Disease (FLUTD), CEVA Animal Health have also produced a highly informative technical review on the subject. Produced in conjunction with Professor Danielle Gunn-Moore, head of the feline clinic at the University of Edinburgh, the eight-page, colour brochure contains practical information on the clinical signs, diagnosis and treatment of FLUTD and also includes behavioural advice on reducing stress in cats, which can be a major cause of FLUTD.
To receive a free copy of CEVA's FLUTD technical review and for further information on Cystease® S, please contact Fraser Broadfoot MRCVS on 01494 781510, CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG.
The Animal Medicines Training Regulatory Authority (AMTRA) is launching its new Continuous Professional Development (CPD) scheme today, designed to ensure that the Authority's registered Suitably Qualified Persons (SQPs) keep up to date with the latest animal medicines information.
In order to maintain their SQP status, every SQP will have to achieve a minimum number of CPD points during each AMTRA CPD period, running for two years from July to June. However, in the initial stages of the scheme, this first period will run for 33 months, from October 2008 to June 2011, allowing AMTRA to fine tune the system if required and give its SQPs time to get used to the new structure.
During these CPD periods, SQPs are required to obtain a minimum number of CPD points depending on their SQP type:
SQP Type: Modules; VPS medicines supplied; CPD PointsR-SQP: FAM+EQM+CAM; All VPS Medicines; 70 pointsG-SQP: FAM+EQM; VPS-farm animals and equines only; 50 pointsK-SQP: FAM+CAM; VPS-farm and companion animals only; 50 pointsE-SQP: EQM+CAM; VPS-equines and companion animals only; 50 pointsL-SQP: FAM; VPS-farm animals only; 30 pointsJ-SQP: EQM; VPS-equines only; 30 pointsC-SQP: CAM; VPS-companion animals only; 30 points
(FAM - Farm Animal Module, EQM - Equine Module, CAM - Companion Animal Module)
In essence, this means that 20 points are required per animal group, plus a further 10 points. Dr Roger Dawson, Secretary of AMTRA comments, "There is no maximum number of CPD points that SQPs can accumulate and we will be encouraging them to gain the benefit of as much CPD as they can."
Those SQPs who do not achieve the minimum number of CPD points by the end of the period will not be eligible to renew their status for the following year. However, such SQPs will have the option of sitting an examination before the end of that CPD period in order to maintain their SQP status and eligible be to renew for the next year.
SQPs will have a range of avenues through which to gain CPD points, ranging from four types of AMTRA-accredited CPD Events, to online study and personal study. With CPD Events and online studies, accreditation and points will be awarded by the AMTRA CPD Accreditation Panel. With personal study, AMTRA accepts a degree of self-certification of this form of CPD, however the points gained in this way are limited to a relatively small proportion of the minimum required in a CPD period.
Throughout a CPD period, all SQPs are required to attend at least ONE CPD Event. These events will comprise a range of modules that will be assessed for coverage, of relevant topics ranging from legislation, regulations and prevalence & effects of parasites and pathogens, to control of disease management, resistance, warnings and SARS.
Dr Dawson says, "The new CPD scheme has the necessary flexibility to allow SQPs to gain the required CPD points via a number of routes, from accredited CPD events and online study to personal study. Furthermore, the structure of the scheme ensures that their studies will be properly assessed to ensure they have gained the necessary knowledge to secure their CPD points."
Dunfermline-based Vets Now Ltd has been announced as the winner of the Scotland regional final of the £35 Million Bank of Scotland Corporate Entrepreneur Challenge. The company, based on Pitreavie Drive, is the UK's leading provider of out of hours emergency care for animals and has secured an incredible funding package of up to £5 million, free of interest and charges for three years, to turn their expansion plans into reality.Richard Dixon, Managing Director of Vets Now Ltd, said, "I am absolutely thrilled that we have won the Scottish regional final of the Entrepreneur Challenge. A lot of time and effort went into our presentation and we knew that the competition was going to be tough. I'm very proud of our team, without who Vets Now would not be what it is today."Winning the Challenge is going to have a fundamental impact on Vets Now, taking our business to a completely new level. The funding will allow us to make substantial growth and move the business into Europe. It will also increase the range of services we can provide to customers and increase the overall profile of our organisation."Richard will now go through to the national final in December, where he will compete against the winners from six other regions across the UK for the chance to be named ‘Entrepreneur of the Year' and the opportunity to benefit from four days mentoring from one of Britain's most successful and high profile entrepreneurs.Vets Now was chosen as the winner after Richard Dixon presented his business case and plans for the future to a panel of judges, including Willie Haughey from City Refrigeration and John Anderson from The Entrepreneurial Exchange. Willie, John and the rest of the judging panel then questioned Richard in their search for an entrepreneur who displayed flair, vision and creativity, coupled with solid business acumen and impressive plans for the future. The judging was followed by a dinner and award ceremony at Stirling Castle, at which the winner was announced.For more information visit http://www.theboschallenge.co.uk/